Aspirin Eases Genitourinary (GU) Toxicity from Prostate Cancer Radiotherapy
Low-dose aspirin decreased the likelihood of acute genitourinary toxicity in prostate cancer by 27%.
Low-dose aspirin use is independently associated with decreased acute genitourinary (GU) toxicity in patients undergoing radiotherapy for prostate cancer (PCa), researchers reported at the American Society for Radiation Oncology 56th annual meeting in San Francisco.
John L. Mikell, MD, and colleagues at Emory University in Atlanta studied 972 PCa patients treated with definitive radiotherapy.
Of these, 210 were on daily low-dose aspirin during treatment. In multivariate analysis, use of low-dose aspirin was associated with a statistically significant 27% decreased risk of acute GU toxicity and no statistically significant worsening of acute gastrointestinal or late GU toxicity, the investigators reported in a poster presentation.
“While these results require validation in a prospective study, aspirin use during radiotherapy for [PCa] should be considered, as low-dose aspirin is a safe, inexpensive medication already separately recommended for many patients planned for radiotherapy,” the authors concluded.